ANIP — ANI Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $1.51bn
- $2.01bn
- $614.38m
- 49
- 35
- 99
- 64
Annual cashflow statement for ANI Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -22.5 | -42.6 | -47.9 | 18.8 | -18.5 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 19 | 15.5 | 23.6 | 27.3 | 47.9 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -12.6 | -0.084 | -51.3 | 24.9 | -11.2 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 15.3 | 3.32 | -31.2 | 119 | 64 |
| Capital Expenditures | -6.13 | -2.56 | -8.88 | -8.87 | -16.2 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -62.2 | -103 | -6.86 | -9.64 | -388 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Change in Net Intangibles | |||||
| Cash from Investing Activities | -68.3 | -105 | -15.7 | -18.5 | -405 |
| Financing Cash Flow Items | — | -19.4 | 0 | -12.5 | -74.2 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -1.44 | 195 | -5.13 | 67.4 | 265 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -54.5 | 92.4 | -52.1 | 168 | -76.2 |